Built from Castle Biosciences, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
CSTL · Nasdaq · Healthcare · Diagnostics and Research
$33.78-2.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $385M to $395M for Fiscal year 2026 — up 13.3% on a year earlier, slower than the 23.9% just reported
The themes Castle Biosciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.$259.4BA+
IDXXIdexx Laboratories Inc.$55.5BA+
IQVIQVIA Holdings Inc.$43.7BA
ILMNIllumina, Inc.$31.3BA+
LHLabcorp Holdings Inc.$30.1BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now AJust reported
From Castle Biosciences's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$102.9M
+24% y/y
-0.6% q/q
Guided
—
No guide given
Actual
-$0.13
Guided
—
No guide given
Actual
-$2.7M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade C-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 27 quarters of Castle Biosciences, Inc.’s grade history. The other 25 go back to May 2020.